View in EDS HTML Full Text PDF Full Text

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Saved in:
Bibliographic Details
Title: Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
Authors: Chen, Zi-Rong1 (AUTHOR), Chueh, Chen-Han1 (AUTHOR), Chiang, Nai-Jung2,3 (AUTHOR) njchiang@vghtpe.gov.tw, Tsai, Yi-Wen1 (AUTHOR) ywtsai@nycu.edu.tw
Source: Cost Effectiveness & Resource Allocation. 9/11/2023, Vol. 21 Issue 1, p1-10. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 171881938
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Chen%2C+Zi-Rong%22">Chen, Zi-Rong</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chueh%2C+Chen-Han%22">Chueh, Chen-Han</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chiang%2C+Nai-Jung%22">Chiang, Nai-Jung</searchLink><relatesTo>2,3</relatesTo> (AUTHOR)<i> njchiang@vghtpe.gov.tw</i><br /><searchLink fieldCode="AR" term="%22Tsai%2C+Yi-Wen%22">Tsai, Yi-Wen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> ywtsai@nycu.edu.tw</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Cost+Effectiveness+%26+Resource+Allocation%22">Cost Effectiveness & Resource Allocation</searchLink>. 9/11/2023, Vol. 21 Issue 1, p1-10. 10p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=171881938
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12962-023-00473-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1
    Titles:
      – TitleFull: Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chen, Zi-Rong
      – PersonEntity:
          Name:
            NameFull: Chueh, Chen-Han
      – PersonEntity:
          Name:
            NameFull: Chiang, Nai-Jung
      – PersonEntity:
          Name:
            NameFull: Tsai, Yi-Wen
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 09
              Text: 9/11/2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 14787547
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cost Effectiveness & Resource Allocation
              Type: main
ResultId 1